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Abstract: 
Background and Purpose: The purpose was to characterize 
18
F-fluorodeoxyglucose-
positron emission tomography (FDG-PET) findings after stereotactic body radiation 
therapy (SBRT) for lung cancer. 
Materials and Methods: This was a retrospective review of 32 FDG-PET scans from 23 
patients who underwent SBRT for lung cancer and who showed no evidence of local 
recurrence. The FDG uptake by lesions was assessed visually using a 3-point scale (0, 
none or faint; 1, mild; or 2, moderate to intense), and the demarcation (ill- or well-
defined) was evaluated. For semi-quantitative analysis, the maximum standardized uptake 
value (SUVmax) was calculated. 
Results: Grade 2 intensity was observed in 70, 33, 30, and 0% of PET scans performed 
<6, 6–12, 12–24, and >24 months, respectively, after SBRT; well-defined demarcation 
was observed in 80, 33, 40, and 17%, respectively, and the respective means of the 
SUVmax were 4.9, 2.6, 3.0 and 2.3. The SUVmax was significantly higher for scans 
performed at <6 months than at 6–12 or >24 months. 
Conclusions: FDG uptake tended to be intense and well-defined at early times after 
SBRT, especially within 6 months, and was faint and ill-defined at later periods. 






Stereotactic body radiation therapy (SBRT) is an important option for the 
treatment of solitary lung cancer, especially in inoperable patients. Initial studies on 
SBRT were reported by Blomgren et al. in 1995 [1] and Uematsu et al. in 1998 [2]. 
Thereafter, many promising outcomes have been reported for SBRT of solitary non-small 
cell lung cancer (NSCLC). We reported our experience in SBRT for primary lung cancer 
[3]. The local control rates for stage I NSCLC were 96.7% for T1a, 84.5% for T1b, and 
78.1% for T2a, respectively. The excellent rates for local control of stage I NSCLC after 
SBRT were also reported by several authors, and they ranged from 77 to 95% [4–7]. 
When SBRT is applied to operable patients, the early detection of local 
recurrence after SBRT is vital for those who may be salvaged with surgery [8]. However, 
it is difficult to detect local recurrence based on computed tomography (CT) alone [9, 
10], because consolidations representing radiation-induced inflammation or fibrosis [11] 
can overlap the tumour and prevent evaluation of local tumour status. 
As a diagnostic imaging tool, positron emission tomography (PET) with 
18
F-
fluorodeoxyglucose (FDG) reveals metabolic changes. FDG-PET currently plays 
important roles in not only staging [12] and restaging [13] but also the prognostic 
assessment of lung cancer [14]. The clinical significance of FDG-PET after conventional 
radiotherapy for NSCLC has been described [15–18], but FDG-PET findings after SBRT 
are limited [19, 20]. Even with FDG-PET, it may be difficult to differentiate between 
recurrence and inflammatory changes. Nevertheless, the recognition of the uptake 
patterns and frequency of FDG accumulation owing to inflammatory processes after 
SBRT would be helpful in interpreting PET images during follow-up. 
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The objective of this study was to characterize the FDG-PET findings in patients 
with lung cancer treated by SBRT. 
 
Materials and methods 
Patients 
Inclusion criteria for this study were as follows: (1) availability of at least one 
FDG-PET scan performed 1 or more months after SBRT and attenuation-corrected PET 
images reconstructed by iterative algorithms; (2) follow-up duration of >12 months; and 
(3) no local recurrence for at least 6 months after the FDG-PET scan. Local recurrence 
was diagnosed based on histological confirmation or continuous enlargement of local 
tumour on CT for 6 months or more. Among 96 patients who underwent SBRT for 
primary lung cancer at our institution between September 1998 and November 2005, 58 
patients, 9 patients and 6 patients were excluded based on the criteria (1), (2) and (3), 
respectively. The remaining 23 patients were eligible for this study. All patients provided 
written informed consent for SBRT and associated researches which were approved by 
the institutional review board. Characteristics of the patients were shown in Table 1. 
Fifteen patients were male; eight were female. The median age of the patients was 77 
years (range, 64–89). The histological findings were adenocarcinoma in 14 patients and 
squamous cell carcinoma in six patients, with unconfirmed diagnoses in three patients. 
The post-SBRT median follow-up duration was 51 months (range, 13–113). 
 
SBRT technique 
Details of the SBRT technique used in the present study have been described in 
our previous study [21]. The patient’s body was immobilized using a stereotactic body 
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frame (Elekta AB, Stockholm, Sweden). SBRT was planned using a commercial 
treatment planning system (CADPLAN or Eclipse; Varian Medical Systems, Inc., Palo 
Alto, CA). The planning target volume (PTV) was defined as the internal target volume, 
which was delineated on long scan-time CT images, with a 5-mm margin for setup 
uncertainty. Multiple non-coplanar static ports (5–8 ports) were arranged for the PTV. 
The prescription dose was 48 Gy, administered in four fractions at the isocenter. 
Irradiation was performed with 6-MV X-ray beams from a linear accelerator (Clinac 
2300 CD; Varian Medical Systems). The median overall treatment time was 11 days 




F-FDG was synthesized by the nucleophilic substitution method, using an 
18
F-
FDG synthesizing instrument (F-100; Sumitomo Heavy Industries, Tokyo, Japan) and a 
cyclotron (CYPRIS-325R; Sumitomo Heavy Industries, Tokyo, Japan). Patients fasted 
for ≥4 h before the intravenous injection of approximately 370 MBq of FDG. Whole-
body PET images with attenuation correction were acquired about 50 min later, using a 
whole-body PET scanner with an 18-ring detector arrangement (Advance; GE 
Healthcare, Milwaukee, WI). The system permitted the simultaneous acquisition of 35 
transaxial images with a 4.25-mm interslice spacing. The transaxial resolution was 4.2 
mm at full width at half maximum, allowing for multidirectional reconstruction of the 
images without loss of resolution. The field of view and pixel size of the reconstructed 
images were 128 mm and 4 mm, respectively. The images were reconstructed by ordered-
subsets expectation maximization algorithm. 
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Evaluation and analysis 
There were a total of 32 FDG-PET scans for the 23 patients, because nine 
patients each had two PET scans. For the analysis, the PET scans were divided into four 
groups according to the time duration between the completion of SBRT and the PET 
scan, which ranged from 1 to 51 months with a median of 12 months: <6 months, 10 
scans; 6–12 months, six scans; 12–24 months, 10 scans; and >24 months, six scans. The 
intensity and pattern of the FDG uptake were evaluated qualitatively and semi-
quantitatively in the pulmonary region, which received a high dose. 
For the qualitative evaluation, the intensity of the FDG uptake was assessed 
visually using a 3-point scale: 0, none or faint uptake; 1, mild uptake, comparable to that 
in the blood pool; and 2, moderate to intense uptake, greater than that in the blood pool. 
The demarcation of the tracer uptake was categorized as well- or ill-defined. The 
qualitative evaluations were determined by a board-certified radiologist and nuclear 
medicine physician (YN) and a board-certified radiation oncologist (YM) on consensus 
without any information about time duration between SBRT and FDG-PET. For the semi-
quantitative analysis, we calculated the maximum standardized uptake value (SUVmax) 
after setting regions of interest. For three scans, although qualitative analysis was 
possible, a reliable SUVmax could not be obtained because of artifacts. Thus, a total of 
29 PET scans were analyzed semi-quantitatively. The SUVmax was calculated as 
follows: 
SUV = FDGregion/ (FDGdose/ WT), where FDGregion is the decay-corrected regional 
18
F-
FDG concentration in Bq/ml, FDGdose is the injected 
18
F-FDG in Bq, and WT is the body 
weight in grams. 




Qualitative evaluation (Fig. 1) 
The numbers of PET scans showing FDG uptake intensity grades of 0, 1, and 2 
for each time category were: 1 (10%), 2 (20%), and 7 (70%) for scans performed at <6 
months; 2 (33%), 2 (33%), and 2 (33%) at 6–12 months; 2 (20%), 5 (50%), and 3 (30%) 
at 12–24 months; and 1 (17%), 5 (83%), and 0 at >24 months. Uptakes with ill-defined 
and well-defined demarcations were observed in 2 (20%) and 8 (80%) scans at <6 
months; 4 (67%) and 2 (33%) scans at 6–12 months, 6 (60%) and 4 (40%) scans at 12–24 
months, and 5 (83%) and 1 (17%) scans at >24 months. The FDG uptake tended to be 
intense and well-defined at early times after SBRT. 
Semi-quantitative evaluation (Fig. 2) 
A moderate negative correlation was observed between the SUVmax and time 
after SBRT (Pearson’s product–moment correlation coefficient = −0.388; p = 0.038). The 
SUVmax (mean ± SD) was 4.9 ± 2.2 at <6 months, 2.6 ± 1.5 at 6–12 months, 3.0 ± 0.9 at 
12–24 months, and 2.3 ± 0.9 at >24 months. The SUVmax at <6 months was significantly 
higher than that at 6–12 months or >24 months (p = 0.042 or 0.020, Tukey HSD test). 
Differences in the SUV max were not significant between 6–12 months, 12–24 months 
and >24 months.  
Changes in FDG uptakes between two scans 
Table 2 shows FDG-PET findings in the nine patients who had two PET scans. 
FDG uptakes in three of the nine patients (Patients A, D and F in Table 2) changed into 
typical findings (i.e. faint intensity, ill-defined demarcation, and less SUVmax) in the 
later periods. A representative case is demonstrated in Fig. 3. No significant change was 
observed in two patients (Patients B and C). The remaining 4 patients (Patients E, G, H 
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and I) showed a higher grade of intensity or a higher SUVmax in the second scan than in 
the first scan. 
 
Discussion 
Two previous reports have described FDG-PET findings after SBRT for lung 





methionine (MET) in nine patients treated with SBRT [19]. The SUV decreased 
gradually with time in five patients, whereas it increased at 2 weeks after SBRT in two 
patients and at >3 months after SBRT in the remaining two patients. Radiation 
pneumonitis was thought to be the cause of this increase; the addition of MET-PET did 
not supply any information beyond that provided by FDG-PET. Hoopes et al. also 
evaluated FDG-PET in patients treated with SBRT [20]. PET analysis was performed in 
28 patients after a median post-SBRT time of 17.3 months (range, 4–48). Four of the 28 
patients showed a high SUV (2.5–5.87) without evidence of local, nodal, or distant 
failure. In the present study, the SUVmax remained high (mean, 2.7; range, 1.3–4.3) at 
≥12 months after SBRT, which is consistent with the results of Hoopes et al. [20]. 
It is important to detect local recurrence soon after SBRT, but this is difficult 
based on CT alone. We have previously evaluated post-irradiation changes and local 
recurrence after SBRT, based on CT [9]. However, in the previous study, we could not 
detect any significant CT differences between radiation-induced inflammatory changes 
and local recurrence. We concluded that early detection of local recurrence is difficult 
using CT because of the dense consolidation, called mass-like consolidation, which was 
observed at a median post-SBRT time of 5 months in 68% of the cases. Most cases (89%) 
of consolidation were confirmed as radiation-induced lung injury, although a few (11%) 
were local recurrence. Takeda et al. reported that 20 of 50 patients had abnormal opacity 
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that was suspicious for local recurrence at a median of 20.7 months after SBRT [10]. 
However, only three patients had recurrence, and the remaining 17 patients were free 
from recurrence or were considered equivocal. They also concluded that it was difficult 
to distinguish radiation fibrosis from local tumour recurrence. 
The value of FDG-PET in detecting residual or recurrent NSCLC after 
conventional radiotherapy has been evaluated by Frank et al. [15] and Bury et al. [16], 
who found a sensitivity and specificity of 100% and 89–92%, respectively. Inoue et al. 
have suggested a threshold SUV of 5.0 for the differential diagnosis between local 
recurrence of lung cancer and post-treatment changes [17]. Indeed, our study had no case 
in which the SUVmax was >5.0 at ≥6 months after SBRT. According to Takeda et al. 
[10], a patient with a SUVmax of 5.0 at 12 months after SBRT developed local 
recurrence, and three patients with a SUVmax of 2.2–3.13 showed no evidence of local 
recurrence. However, Hoopes et al. [20] reported that two patients with a SUV >5.0 at 
23–26 months were free from local recurrence. Further studies are needed to investigate 
an optimal SUV for distinguishing local recurrence from post-SBRT changes. As far as 
we are aware, there have been no studies to date regarding FDG-PET detection of local 
recurrence after SBRT. 
The present study has some limitations. First, the study was not prospective but 
was a retrospective review. FDG-PET was performed in a limited number of patients, 
some of whom had a suspicious consolidation upon CT, which might have caused 
selection bias. Second, local control was not based on pathological confirmation but on 
CT images. Therefore, FDG uptake demonstrating recurrent tumours might have been 
included with that owing to inflammation caused by irradiation. However, clinically 
suspicious recurrent cases were not included, and a median follow-up duration of 51 
months was sufficient to establish no recurrence of local tumours. 
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In conclusion, this study showed that FDG uptake tended to be high and well-
defined during an early time period after SBRT, especially within the initial 6 months, 
and became lower and ill-defined during later periods. Moderate to intense FDG uptake 
observed during an early period after SBRT does not always indicate residual or recurrent 
tumour. These findings may help in interpreting FDG-PET data for follow-up in patients 
with NSCLC after SBRT. 
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Figure legends: 
Fig. 1 Visual analysis of FDG uptake regarding intensity (a) and demarcation (b). 
Intensity was classified into three grades: 0, none or faint uptake; 1, mild uptake, 
comparable to that in the blood pool; and 2, moderate to intense uptake, greater than that 
in the blood pool. The prevalence of intense and well-defined uptake gradually decreased 
with time after treatment. 
 
Fig. 2 SUVmax in FDG-PET and the time duration between SBRT and FDG-PET. 
(a) Scatter plot of SUVmax versus time after SBRT, showing a moderately negative 
correlation coefficient of –0.388. 
(b) Mean (diamond) and SD (vertical bar) of SUVmax for FDG-PET performed at 
different times after SBRT: <6 months, 6–12 months, 12–24 months, and >24 months. 
The SUVmax at <6 months was significantly higher than that at 6–12 or >24 months. 
 
Fig. 3. 79-year-old woman (Patient D in Table 2) with cT2N0M0 primary lung 
adenocarcinoma, who underwent SBRT with a prescription dose of 48 Gy administered 
in four fractions at the isocenter 
(a) CT image before treatment (left) and dose distribution of SBRT (right). The inner thin 
dashed, solid, and outer dashed lines indicate 48, 40, and 20-Gy isodose lines, 
respectively. 
(b) CT and FDG-PET images 2 months after SBRT. Radiation pneumonitis is observed 
upon CT (arrowhead). The FDG-PET scan shows well-defined and intense (grade 2) 
uptake (arrows) with the SUV max of 7.1. 
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(c) CT at 52 months and FDG-PET at 49 months; CT shows a scar-like shadow 
(arrowhead). Ill-defined and mild (grade 1) uptake is seen upon FDG-PET (arrows). The 
SUVmax was 3.0. 
 
Tables: 
Table 1. Patient characteristics 
Sex  
 Male  15 
 Female 8 
Age (median; range) 77; 64–89 
Histology  
 Adenocarcinoma  14 
 Squamous cell carcinoma 6 
 Unconfirmed 3 
 
Table








37  1 well 1.3  
51  1 ill 1.3  
B 
21  1 ill NA 
46  1 ill 3.6  
C 
2  0 ill 1.5  
9  0 ill 1.6  
D 
2  2 well 7.1  
49  1 ill 3.0  
E 
13  1 ill 2.6  
24  1 ill 3.1  
F 
1  2 well 5.1  
14  1 well 2.5  
G 
1  1 well 2.1  
13  2 well 3.8  
H 
2  1 ill 2.7  
12  2 ill 4.7  
I 
11  1 ill 3.1  
23  2 ill 4.3  
Abbreviations: SBRT = stereotactic body radiation therapy, SUVmax = maximum 
standardized uptake value, NA = not available 



























































PET (axial) PET (coronal)
cCT (axial)
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